Drug intelligence / Profile preview

CB-106

Development stage: Preclinical
Lead developer: Chimeron Bio
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CB-106 is a self-amplifying RNA (saRNA) COVID-19 vaccine candidate developed by Chimeron Bio. It utilizes Chimeron's proprietary ChaESAR™ technology platform. The vaccine is currently undergoing preclinical evaluation in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to test its efficacy in hamster models and generate data to support advancement into non-human primate studies.

Other names: ChaESAR COVID-19 vaccine

Beyond the preview

Go deeper on CB-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-106.

Explore the full profile